Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma.

Abstract

Gemcitabine is a nucleoside analogue that has shown to have antineoplastic activity in different solid tumours (lung, pancreas, bladder, colon, ovarian, and breast cancer) and malignant mesothelioma. The toxic effects of gemcitabine include myelosuppression, flu-like syndrome, altered liver function tests, bronchospasm, rash, itching, and fever. However, gemcitabine-induced erysipeloid skin reaction was reported in a small number of patients with previous history of radiotherapy or lymphedema. We reported a male patient who developed erysipeloid skin reaction following gemcitabine treatment in the absence of radiotherapy and lymphedema.

• Authors: I Kuku, E Kaya, A Sevinc, I Aydogdu
• Journal: Journal of the European Academy of Dermatology and Venereology : JEADV (J Eur Acad Dermatol Venereol) Vol. 16 Issue 3 Pg. 271-2 (May 2002) ISSN: 0926-9959 [Print] England
• PMID: 12195570 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Deoxycytidine
• Gemcitabine

Topics

• Antimetabolites, Antineoplastic (adverse effects, therapeutic use)
• Deoxycytidine (adverse effects, analogs & derivatives, therapeutic use)
• Drug Eruptions (etiology)
• Erysipeloid (chemically induced)
• Humans
• Liver Neoplasms (drug therapy)
• Male
• Mesothelioma (drug therapy)
• Middle Aged
• Gemcitabine